Medicine and Dentistry
Adverse Event
9%
Antiplatelet Drug
9%
Association
9%
Blood
9%
Clopidogrel
100%
Cohort Analysis
9%
Combination Therapy
9%
Diagnosis
9%
Incidence
9%
Laboratory
9%
Mechanism of Action
9%
Patient
81%
Physician
9%
Plasma Exchange
18%
Relapse
9%
Surveillance
9%
Syndrome
9%
Therapeutic Procedure
27%
Thienopyridine
9%
Thrombotic Thrombocytopenic Purpura
100%
Ticlopidine
36%
Nursing and Health Professions
Adverse Event
9%
Antithrombocytic Agent
9%
Blood Bank
9%
Clinical Practice
9%
Clopidogrel
100%
Cohort Analysis
9%
Combination Therapy
9%
Diagnosis
9%
Hematologist
9%
Incidence
9%
Laboratory
9%
Physician
9%
Plasma Exchange
18%
Relapse
9%
Syndrome
9%
Thienopyridine Derivative
9%
Thrombotic Thrombocytopenic Purpura
100%
Ticlopidine
36%
INIS
banks
11%
blood
11%
clinical trials
11%
drugs
11%
laboratories
11%
manufacturers
11%
patients
100%
plasma
22%
purpura
100%
surveillance
11%
therapy
11%
Biochemistry, Genetics and Molecular Biology
Association
9%
Chemical Structure
9%
Clinical Trial
9%
Clopidogrel
100%
Cohort Study
9%
Incidence
9%
Relapse
9%
Thienopyridine
9%
Thrombotic Thrombocytopenic Purpura
100%
Ticlopidine
36%
Pharmacology, Toxicology and Pharmaceutical Science
Adverse Event
9%
Antithrombocytic Agent
9%
Clopidogrel
100%
Incidence
9%
Relapse
9%
Syndrome
9%
Thienopyridine
9%
Thrombotic Thrombocytopenic Purpura
100%
Ticlopidine
36%